Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

Published

Journal Article

Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous drug use accounted for 6. Four subjects received placebo, 13 received a complete immunization schedule (> or = 3 injections), and 6 were partially immunized (< or = 2 injections). There was no significant difference between vaccine recipients and control groups in incidence of HIV-1 infection, virus load, CD4 lymphocyte count, or V3 loop amino acid sequence. In summary, 19 vaccinated subjects acquired HIV-1 infection during phase I and II trials, indicating that immunization with the products described is < 100% effective in preventing or rapidly clearing infection. Laboratory analysis suggested that vaccine-induced immune responses did not significantly affect the genotypic or phenotypic characteristics of transmitted virus or the early clinical course of HIV-1 infection.

Full Text

Cited Authors

  • Graham, BS; McElrath, MJ; Connor, RI; Schwartz, DH; Gorse, GJ; Keefer, MC; Mulligan, MJ; Matthews, TJ; Wolinsky, SM; Montefiori, DC; Vermund, SH; Lambert, JS; Corey, L; Belshe, RB; Dolin, R; Wright, PF; Korber, BT; Wolff, MC; Fast, PE

Published Date

  • February 1998

Published In

Volume / Issue

  • 177 / 2

Start / End Page

  • 310 - 319

PubMed ID

  • 9466516

Pubmed Central ID

  • 9466516

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1086/514209

Language

  • eng

Conference Location

  • United States